1. Thorat MA et al. Prognostic role and impact of multi-clonal ER and PgR expression in ductal carcinoma in situ: Results from the UK/ANZ DCIS trial. 38th Annual SABCS Dec. 8-12, 2015.
2. Thorat MA et al. Prognostic and predictive relevance of HER2 status in ductal carcinoma in situ: Results from the UK/ANZ DCIS trial. 38th Annual SABCS Dec. 8-12, 2015.
3. Schneider BP, Radovich M, Hancock B, Kassem N, Sledge G, Nielsen KV, Thorat M, Mehta R, Badve S. VEGFA Amplification/Deletion in Human Breast Tumors. Mod Pathol 2012; 25(Suppl 2):65A-Abstract 261.
4. Badve SS, Li L, Thorat MA, Gagnon RC, Ellis CE, O'Shaughnessy J, Blackwell KL, Baselga J, Sledge GW. Differential gene expression analysis and correlation with outcome in HER2-positive metastatic breast cancer treated with HER2-targeted therapy. J Clin Oncol 28:15s, 2010 (suppl; abstr 1036)
5. Ademuyiwa FO, Miller A, Edge SB, Thorat MA, Sledge GW, Badve SS. The effects of Oncotype DX recurrence scores on chemotherapy receipt in a multi-institutional breast cancer cohort. J Clin Oncol 28:15s, 2010 (suppl; abstr 669)
6. Schneider BP, Radovich M, Hancock BA, Kassem N, Vance GH, Sledge GW, Nielsen KV, Müller S, Thorat MA, Badve SS. VEGFA amplification/deletion in human breast tumors. J Clin Oncol 28, 2010 (suppl; abstr e21017)
7. Jain RK, Thorat MA, Mehta R, Polar Y, Morimiya A, Sweeney C, Beck S, Ulbright TM, Badve S. Gene Expression Profiles of Classical and Spermatocytic Seminoma. Mod Pathol 2010;23:877.
8. Al-Azzawi HH, Pitt HA, Swartz-Basile DA, Wang S, Dalbec KM, Thorat MA, et al. Obesity downregulates innate and adaptive immunity genes in the pancreatic cancer microenvironment. Journal of the American College of Surgeons. 2009; 209 (3, Supplement 1):S118-S9.
9. Badve S, Shen C, Thorat M, Li L, Gagnon R, Koehler M, et al. 5BA Identification of gene expression profiles that predict response to HER2-targeted therapy. European Journal of Cancer Supplements 2009;7(3):5.
10. Thorat MA, Ademuyiwa FO, Nakshatri H, Badve S. Expression of FOXA1, Estrogen Receptor Associated Transcription Factor, Correlates with Oncotype Dx Recurrence Score. Modern Pathology. 2009 Jan; 89(Suppl 1):72A-Abstract 312.
11. Bowling M, Goulet R, Clare S, Rager E, Bowyer-Cherry M, Blosser R, Thorat M, Sunil Badve. Intraoperative Molecular Pathology of Sentinel Axillary Lymph Nodes in Breast Carcinoma Patients. American Society of Breast Surgeons, 10th Annual Meeting, San Diego, CA; April 22-26, 2009.
12. Duchnowska R, Jassem J, Shen C, Thorat M, Li L, et al. Molecular characteristics of matched brain metastasis (BM) versus the primary breast cancer (PBC). Cancer Res. 2009 Jan;15 69(2):164S-164S.
13. Thorat MA, Shet TM, Morimiya A, Chinoy RF, Badwe RA, Badve S. Comparison of the gene expression profiles of metaplastic breast cancer and basal-like breast cancer. ASCO Breast Cancer Symposium, Washington DC; September 5-7, 2008.
14. Thorat MA, Badve S. Nuclear expression of Vascular Endothelial Growth Factor Receptor-2 in lobular breast cancers: confirmation of serendipitous observation. ASCO Breast Cancer Symposium, Washington DC; September 5-7, 2008.
15. McCune KR, Bhat-Nakshatri P, Thorat M, Badve S, Nakshatri H. Control of Luminal Type (Lum) A Subtype Enriched Transcription Factor Network by Insulin: Implications of Diabetes on Breast Cancer Classification. Cancer Res. 2009 Jan;15 69(2):213S-214S.
16. Resetkova E, Thorat M, Badve S. Expression of ALDH1 (putative cancer stem cell marker) does not correlate with response to neoadjuvant chemotherapy (NACT) in breast carcinoma.Histopathology. 2008 Oct; 53(Suppl 1):59-60-Abstract 134.
17. Badve S, Thorat M, Reis-Filho J. Cytoplasmic expression of ALDH1 correlates with breast cancer subtypes. Histopathology. 2008 Oct; 53(Suppl 1):26-Abstract 058.
18. Nakshatri H, Mccune KR, Bhat-Nakshatri P, Thorat M, Badve S. Control of Luminal type A intrinsic subtype enriched transcription factor network by insulin: implications of diabetes on breast cancer subtypes. Era of Hope Meeting. Baltimore, MD; June 25—28, 2008.
19. Thorat MA, Saxena R, Badve S. Regulatory T cells (T-Regs) in breast cancer sentinel nodes (SN): FOXP3 expression analysis. J Clin Oncol 26: 2008 (May 20 suppl; abstr 22175).
20. Duchnowska R, Jassem J, Thorat MA, Morimiya A, Sledge G, Li L, Biernat W, Szczylik C, Steeg P, Badve S. Gene expression analysis for prediction of early brain metastasis (BM) in HER2-positive (HER2+) breast cancer patients (pts). J Clin Oncol 26: 2008 (May 20 suppl; abstr 1019).
21. Gökmen-Polar Y, Thorat MA, Turbin D, Tuzmen S, Leung S, Huntsman DG, Badve S, Sledge GW. Differential subcellular expression of protein kinase C betaII in breast cancer – correlation with breast cancer subtypes. Proceedings of the AACR Annual Meeting Apr 2008; 49: 662.
22. Hancock BA, Radovich M, Badve S, Thorat MA, Azzouz F, Schneider BP. Association of Single Nucleotide Polymorphisms in Angiogenesis Genes with Expression of VEGF & VEGFR-2 in Breast Carcinoma. Proceedings of the AACR Annual Meeting Apr 2008; 49: 66.
23. Marchio C, Thorat MA, Morimiya A, Savage K, Nakshatri H, Reis-Filho JS, Badve S. FOXA1: A prognostic and Luminal Subtype A marker in Breast Cancer. Modern Pathology. 2008 Jan;21 (Suppl 1):45A-Abstract 194.
24. Thorat MA, Morimiya A, Sledge G, Badve S. Characterization of Estrogen Receptor Positive breast cancers: Gene expression analysis of archived tumours. Breast Cancer Research and Treatment. 2007 Dec;106 (Suppl 1):S243-S.
Kand PG, Nair N, Nilegaonkar S, Thorat M, Badwe R. Emerging role for Dual point FDG-PET imaging in suspected breast carcinoma. World Congress of Nuclear Medicine and Biology, Seoul, Korea, October 2006 (FP116856).